Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches
BRIDGEWATER, N.J.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that the Food and Drug Administration recently accepted Amneals 505(b)(2) New Drug Application for a newly licensed dihydroergotamine (DHE)…
